Mitochondrial and cellular research tools
SS-31 Research: Cardiolipin Targeting and Mitochondrial Models
A research-focused SS-31 article centered on elamipretide, cardiolipin interaction, mitochondrial models, and evidence boundaries.
SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide studied for interaction with cardiolipin on the inner mitochondrial membrane. That mechanism makes it an important research topic, but not a broad energy or anti-aging product claim.
Mechanistic literature
A 2013 JASN paper reported that SS-31 can interact with cardiolipin in ischemic mitochondria models. A later Communications Biology paper examined elamipretide in cardiac ischemia-reperfusion research and cristae-network structure. translational literature in Barth syndrome shows translation into controlled study settings, while a 2025 review summarizes newer mechanism-of-action work.
The Adria emphasis is cardiolipin binding, mitochondrial membrane context, model design, and evidence limits.
Documentation context
Mitochondrial peptide studies are sensitive to model, endpoint, and material identity. A useful research record should include sequence, batch, COA, storage conditions, and any available analytical confirmation.
Adria research-use note
SS-31 is discussed here for lawful laboratory research only. This article does not provide non-laboratory-use, non-laboratory-use, practical-use, energy, disease, or applied-use guidance.
How to read this research
The added value in SS-31 literature is the link between mitochondrial inner-membrane context and measured changes in cardiolipin-linked model systems. A useful reading pass should separate compound identity, cell or tissue model, mitochondrial marker, and functional readout.
For documentation, the important details are sequence identity, purity method, storage conditions, and whether the paper measured mechanism markers directly or inferred them from downstream observations.
Evidence checkpoints for this topic
SS is most useful in the archive when it is read through mitochondrial, oxidative-stress, senescence, telomerase, and gene-expression model literature. A stronger article does not only name a peptide or pathway; it explains what kind of evidence the source actually provides and what remains outside the source.
In this article, sources such as SS-31 and cardiolipin interaction in ischemic mitochondria models, Elamipretide and cristae-network fragmentation research, Elamipretide Phase 2/3 Barth syndrome study should be read for their specific methods, endpoints, and limits. That makes the article more useful for a research archive because a reader can see whether a statement comes from a primary experiment, a review, a mechanistic assay, or a documentation-style discussion.
- Model: check cell type, tissue model, stress condition, telomerase assay, mitochondrial marker panel, or model-organism endpoint.
- Endpoint: record cardiolipin-linked markers, AMPK signaling, oxidative-stress endpoints, telomerase activity, telomere markers, or senescence-marker panels.
- Comparator: verify the stressor, control group, assay platform, marker timing, and whether the source is mechanistic or review-level.
- Documentation: keep sequence identity, batch traceability, COA context, storage condition, and source link together.
- Limit: keep visible the boundary between a marker change and a broad claim about system-level biology.
What a careful reader can take from it
The practical value of this post is the structure it gives to the literature. Instead of treating every source as equal, the reader can separate the question being asked, the method used to ask it, and the claim that can reasonably follow. That is especially important in peptide topics, where online summaries often compress receptor data, model endpoints, supplier documentation, and broad interpretation into one sentence.
For Adria, the useful standard is simple: every strong sentence should be traceable to a source, every source should be described by its model and endpoint, and product-adjacent language should point back to analytical documentation rather than unsupported claims. This is why the article keeps PubMed, PMC, DOI, or documentation links visible instead of hiding the evidence trail.